Neurologic oral manifestations caused by a new formulation of mirtazapine.
Kling
A
A
Division of Clinical Pharmacology, Department of Pharmacology and Clinical Neurosciences, Umeå University, Umeå, Sweden. anders.kling@pharm.umu.se
Dahlqvist
R
R
Johansson
S
S
Bäckström
M
M
Mjörndal
T
T
D000284:Administration, Oral; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005121:Extremities / Q000503:physiopathology; D006801:Humans; D007473:Ion Channels / Q000187:drug effects / Q000502:physiology; D008803:Mianserin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000078785:Mirtazapine; D009055:Mouth / Q000187:drug effects / Q000503:physiopathology; D009638:Norepinephrine / Q000502:physiology; D010146:Pain / Q000139:chemically induced / Q000503:physiopathology; D010292:Paresthesia / Q000139:chemically induced* / Q000503:physiopathology; D011358:Product Surveillance, Postmarketing / Q000706:statistics & numerical data*; D011941:Receptors, Adrenergic / Q000187:drug effects / Q000502:physiology; D011985:Receptors, Serotonin / Q000187:drug effects / Q000502:physiology; D012701:Serotonin / Q000502:physiology; D013548:Sweden
D000929:Antidepressive Agents, Tricyclic; D007473:Ion Channels; D011941:Receptors, Adrenergic; D011985:Receptors, Serotonin; D008803:Mianserin; D012701:Serotonin; D000078785:Mirtazapine; D009638:Norepinephrine